An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC).

被引：3

作者：

Kabbinavar, Fairooz F.

Zomorodian, Nazy

Rettig, Matthew

Khan, Faraz

Greenwald, Daniel Reif

DiCarlo, Brian

Davidson, Sheldon J.

Patel, Ravindranath

Pandit, Lalita

Chandraratna, Rosh

Sanders, Martin

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Los Angeles, CA 90095 USA

[2] VA Greater Los Angeles Healthcare Syst, Dept Med, West Los Angeles, CA USA

[3] Tanslat Res Oncol US, Los Angeles, CA USA

[4] Translat Oncol Res Int, Santa Maria, CA USA

[5] Lalita Pandit MD Inc, Fountain Valley, CA USA

[6] Therapeut Inc, Santa Ana, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期

关键词：

D O I：

10.1200/jco.2014.32.4_suppl.169

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

169

引用

页数：1

共 50 条

[1] An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC).
Kabbinavar, Fairooz F.
Zomorodian, Nazy
Rettig, Matthew
Khan, Faraz
Greenwald, Daniel Reif
Davidson, Sheldon J.
DiCarlo, Brian Anthony
Patel, Ravi
Pandit, Lalita
Chandraratna, Rosh
Sanders, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[2] Management of Castration-Resistant, Taxane-Resistant Prostate Cancer
Beer, Tomasz M.
ONCOLOGY-NEW YORK, 2017, 31 (08): : 633 - 636
[3] Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study
Barata, Pedro C.
Cooney, Matthew
Mendiratta, Prateek
Tyler, Allison
Dreicer, Robert
Garcia, Jorge A.
INVESTIGATIONAL NEW DRUGS, 2018, 36 (06) : 1085 - 1092
[4] Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study
Pedro C. Barata
Matthew Cooney
Prateek Mendiratta
Allison Tyler
Robert Dreicer
Jorge A. Garcia
Investigational New Drugs, 2018, 36 : 1085 - 1092
[5] A phase II trial of zoptarelin doxorubicin in castration- and taxane-resistant prostate cancer.
Yu, Steven
Athreya, Kanthi
Liu, Stephen V.
Schally, Andrew V.
Groshen, Susan G.
Tsao-Wei, Denice D.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
[6] A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer
Yu, Steven S.
Athreya, Kanthi
Liu, Stephen V.
Schally, Andrew V.
Tsao-Wei, Denice
Groshen, Susan
Quinn, David I.
Dorff, Tanya B.
Xiong, Shigang
Engel, Jurgen
Pinski, Jacek
CLINICAL GENITOURINARY CANCER, 2017, 15 (06) : 742 - 749
[7] A Phase I/II Trial of AN-152 in Castration- and Taxane-Resistant Prostate Cancer
Liu, S. V.
Schally, A. V.
Dorff, T. B.
Groshen, S.
Hawes, D.
Quinn, D. I.
Tai, Y. C.
Block, N. L.
Engel, J.
Pinski, J.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S497 - S497
[8] Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer
Dahut, William L.
Madan, Ravi A.
Karakunnel, Joyson J.
Adelberg, David
Gulley, James L.
Turkbey, Ismail B.
Chau, Cindy H.
Spencer, Shawn D.
Mulquin, Marcia
Wright, John
Parnes, Howard L.
Steinberg, Seth M.
Choyke, Peter L.
Figg, William D.
BJU INTERNATIONAL, 2013, 111 (08) : 1269 - 1280
[9] Proxalutamide in metastatic castration-resistant prostate cancer: Primary analysis of a multicenter, randomized, open-label, phase 2 trial
Zhou, Tie
Qin, Shengfei
Xu, Weidong
Tang, Shouyan
Chen, Guanghua
Li, Song
Hou, Jianguo
Gao, Xu
Shi, Guowei
Sun, Zhongquan
Jin, Jie
Chen, Lijun
Sun, Weibing
Liu, Ben
Wang, Jingen
Meng, Qinggui
Wang, Dongwen
Hu, Zhiquan
He, Dalin
Yang, Yong
Song, Xishuang
Fu, Cheng
Wang, Yinhuai
Ye, Dingwei
Zhang, Wei
INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (04) : 792 - 802
[10] COMBINATION THERAPY WITH PARP INHIBITOR AND STATIN FOR CASTRATION-RESISTANT AND TAXANE-RESISTANT PROSTATE CANCER
Sekine, Yoshitaka
Oka, Daisuke
Nakayama, Hiroshi
Miyazawa, Yoshiyuki
Koike, Hidekazu
Matsui, Hiroshi
Shibata, Yasuhiro
Suzuki, Kazuhiro
JOURNAL OF UROLOGY, 2019, 201 (04): : E1174 - E1174

← 1 2 3 4 5 →